...
首页> 外文期刊>American Journal of Cancer Research >Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia
【24h】

Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia

机译:了解敌人以及手中的武器:慢性淋巴细胞白血病的异常死亡途径和治疗药物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematologic malignancy and characterized by dysregulation of cell death pathways. Apoptosis and necroptosis are the two major cell death processes, and substantial evidence showed up-regulation of several pro-survival factors in CLL cells. Autophagy, as a dual player in mediating cell death and survival, is largely regarded to be an alternative target in the treatment of CLL. Numerous novel drugs have been developed and are being investigated in clinical trials. It is necessary to depict the impaired cell death pathways in CLL and the pro-survival factors targeted by noncytotoxic drugs directly or indirectly. Here we summarize three dysregulated cell death mechanisms in CLL, and present the current knowledge of drugs that orchestrate cell death via targeting pro-survival factors and the clinical effects as well.
机译:慢性淋巴细胞性白血病(CLL)是高度异质的血液系统恶性肿瘤,其特征在于细胞死亡途径的失调。凋亡和坏死性坏死是两个主要的细胞死亡过程,大量证据表明CLL细胞中几种促存活因子的上调。自噬作为介导细胞死亡和存活的双重角色,在很大程度上被认为是治疗CLL的替代目标。已经开发出许多新药,并且正在临床试验中进行研究。有必要描述CLL中细胞死亡途径受损和非细胞毒性药物直接或间接靶向的生存因子。在这里,我们总结了CLL中三种失调的细胞死亡机制,并介绍了通过靶向促生存因子来协调细胞死亡的药物的当前知识以及临床效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号